Discovery Pre-Clinical Phase 1 Phase 2 Phase 3

CRN04777, Oral SST5 Agonist


Our team has discovered potent, drug-like, selective, nonpeptide, SST5 receptor agonists designed to suppress insulin secretion and prevent the hypoglycemia observed in children who have congenital hyperinsulinism.

For the Treatment of Congenital Hyperinsulinism


Infants with congenital hyperinsulinism (congenital HI) are born with mutations that cause excess secretion of the pancreatic hormone insulin, resulting in profound hypoglycemia, a very low level of blood glucose. This loss of homeostatic control of blood glucose levels can lead to seizures, developmental disorders, learning disabilities, coma, and even death.

We have identified a product candidate that has entered preclinical development. Our ongoing efforts focus on identifying and advancing into human clinical trials the first oral, selective, nonpeptide, somatostatin type 5 receptor (SST5) agonist designed to treat congenital HI.

Discovery and Identification of Late Stage, Selective, Nonpeptide, Somatostatin Subtype 5 (SST5) Agonists for the Treatment of Hyperinsulinemic Hypoglycemia

Melissa A. Fowler, Jian Zhao, Emmanuel Sturchler, Elizabeth Rico-Bautista, Rosalia de Necochea-Campion, Jon Athanacio, Taylor A. Kredel, Agnes Antwan, Michael Johns, Oleg Tsivkoski, Shimiao Wang, Rosa Luo, Ana K. Kusnetzow, Ajay Madan, R. Scott Struthers, Stacy Markison, Yun Fei Zhu, Stephen F. Betz. ENDO Online 2020. June 8-22, 2020.

Selective Nonpeptide Somatostatin Receptor Subtype 5 (sst5) Agonists Suppress Glucose and Sulfonylurea-induced Insulin Secretion in Rats

Selective Nonpeptide Somatostatin Receptor Subtype 5 (sst5) Agonists Suppress Glucose- and Sulfonylurea-induced Insulin Secretion in Rats

Emmanuel Sturchler, Melissa A. Fowler, Jon Athanacio, Taylor A. Kredel, Michael Johns, Jian Zhao, Shimiao Wang, Rosa Luo, Ana Karin Kusnetzow, Yun Fei Zhu, Ajay Madan, R. Scott Struthers, Stephen F. Betz, Stacy Markison. ENDO 2019. March 23-26, 2019; New Orleans.


Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Induced Insulin Secretion in Pancreatic Islets from both Rats and Healthy Human Donors.

Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Induced Insulin Secretion in Pancreatic Islets from both Rats and Healthy Human Donors.

Elizabeth Rico-Bautista, Ana Karin Kusnetzow, Melissa A. Fowler, Jon Athanacio, Taylor A. Kredel, Jian Zhao, Shimiao Wang, Stacy Markison, Yun Fei Zhu, R. Scott Struthers, Stephen F. Betz. ENDO 2019. March 23-26, 2019; New Orleans.